William James, a partner in Goodwin's IP Litigation Group, explains why the FDA elected to take Sandoz Inc.'s latest application for its etanercept biosimilar to an advisory committee to get its advice on whether to license the product.
Read the full Scrip article here.
Related Content
- AlertMarch 12, 2024
USPTO’s New Guidance on AI-Assisted Inventions: The Impact on the Use of AI in the Life Sciences
- AlertFebruary 13, 2024
USPTO Issues New Guidance on Patenting AI-Assisted Inventions
- InsightJanuary 16, 2024
What’s Next for AI? Six Areas to Watch in 2024
- InsightNovember 30, 2023
How To Reduce the Risk of Copyright Infringement When Using Generative AI To Write Code
- InsightOctober 31, 2023
Coding with AI in an Open-Source World
- AlertAugust 30, 2023
In re Cellect: Federal Circuit Opens New Path for Double Patenting Challenges
- AlertAugust 29, 2023
Biden Executive Order Puts Focus on Domestic Manufacturing of Inventions Created Using Federal Funding
- AlertJuly 17, 2023
Sens. Tillis and Coons Propose New Legislation Regarding Patentability Under § 101
- Speaking EngagementsApril 29, 2024 | 10:15 AM - 11:15 AM PT
PLI's Patent Law Institute 2024: Critical Issues & Best Practices San Francisco
- EventsApril 24, 2024
Dispute Resolution in the Life Sciences Industry
- Speaking EngagementsMarch 28, 2024
The Fate of the Therapeutic Dosing Regimen: Trends and Considerations in Validity Challenges to Dosing Patent Claims
- WebinarMarch 27, 2024
Abortion at the Supreme Court (Again)
- Awards and RankingsMarch 25, 2024
Three Goodwin Lawyers Named to Law360’s 2024 Editorial Advisory Boards
- Press ReleaseMarch 13, 2024
Leading PTAB Partner Lori Gordon Joins Goodwin’s Intellectual Property Litigation Practice in Washington, DC
- Press ReleaseMarch 8, 2024
NAPCO Securities Technologies Completes $81.5 Million Secondary Offering
- In the PressMarch 6, 2024
Eidos Therapeutics Signs Exclusive License Agreement with Bayer